152 related articles for article (PubMed ID: 8368048)
21. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
[TBL] [Abstract][Full Text] [Related]
23. [Therapy of chronic myeloid leukemia with interferon-alpha. A decade of experiences].
Freund M; Heussner P; Hild F; Nowak R; Grote-Metke A; Diedrich H; Koch O; Otremba B; von Wussow P; Kleine HD; Meran J; Link H; Hinrichs HF; Balleisen L; Fonatsch C; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():18-25. PubMed ID: 8692114
[TBL] [Abstract][Full Text] [Related]
24. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
25. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
Ezaki K
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
[No Abstract] [Full Text] [Related]
26. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M;
Haematologica; 2008 May; 93(5):770-4. PubMed ID: 18367490
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
28. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
29. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Buesche G; Freund M; Hehlmann R; Georgii A; Ganser A; Hecker H; Heimpel H; Fonatsch C; Heinze B; Pfirrmann M; Holgado S; Schmeil A; Tobler A; Hasford J; Buhr T; Kreipe HH;
Leukemia; 2004 Sep; 18(9):1460-7. PubMed ID: 15284854
[TBL] [Abstract][Full Text] [Related]
30. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
Mahon FX; Fabères C; Montastruc M; Si-Mour S; Boiron JM; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Pigneux A; Bernard P; Broustet A; Reiffers J
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S33-7. PubMed ID: 8769698
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group.
Thaler J; Hilbe W
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S25-8. PubMed ID: 8769696
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
33. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
[TBL] [Abstract][Full Text] [Related]
34. Intensive combination chemotherapy in treatment of CML.
Lengfelder E; Hehlmann R
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S55-7. PubMed ID: 8769703
[TBL] [Abstract][Full Text] [Related]
35. [Molecular-cytogenetic monitoring of different regimens of treatment in patients with chronic myeloid leukemia].
Diachenko LV; Zakharova AV; Aseeva EA; Turkina AG; Khoroshko ND; Vodinskaia LA; Udovichenko AI; Domracheva EV
Ter Arkh; 2004; 76(7):41-4. PubMed ID: 15379126
[TBL] [Abstract][Full Text] [Related]
36. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
37. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
39. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
Verbeek W; König H; Boehm J; Kohl D; Lange C; Heuer T; Scheibenbogen C; Reis HE; Hochhaus A; Graeven U
Acta Haematol; 2006; 115(1-2):109-12. PubMed ID: 16424660
[TBL] [Abstract][Full Text] [Related]
40. [Interferon-alpha therapy].
Tojo A
Nihon Rinsho; 2001 Dec; 59(12):2383-8. PubMed ID: 11766343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
